指南与共识头颈甲状腺与浅表技术与安全PET

ACR-ACNM-ARS-SNMMI-SPR实践参数:碘-131碘化钠治疗良恶性甲状腺疾病

ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium Iodide.
指南 / 共识 · Am J Clin Oncol · 2025-07-22

该实践参数由美国放射学会(ACR)、美国核医学学会(ACNM)、美国镭学会(ARS)、核医学与分子影像学会(SNMMI)及儿科放射学会(SPR)共同制定,旨在指导经适当培训和许可的医师口服碘-131碘化钠治疗良性和恶性甲状腺疾病,内容涵盖最佳治疗程序、适当预防措施及特殊情形下的治疗。

要点

  • 碘-131碘化钠通过发射高能β粒子产生电离辐射发挥治疗作用,用于甲状腺功能亢进症和分化型甲状腺癌。
  • 治疗需由负责患者临床管理的临床医师与实施放射性药物治疗的医师密切合作与沟通。
  • 文件提供最佳治疗程序、适当预防措施及特殊情形下治疗的指导。

核心结论

  • 该实践参数旨在协助执业医师为良恶性甲状腺疾病患者提供适当的碘-131碘化钠放射学治疗。

研究设计与样本

  • 由美国放射学会(ACR)、美国核医学学会(ACNM)、美国镭学会(ARS)、核医学与分子影像学会(SNMMI)及儿科放射学会(SPR)合作制定的实践参数。
  • 按照ACR网站所述「ACR实践参数与技术标准制定流程」修订,由ACR核医学与分子影像委员会实践参数委员会、放射肿瘤学委员会实践参数委员会、儿科放射学委员会实践参数委员会与ACNM、ARS、SNMMI及SPR合作完成。

诊断标准与关键数值

  • 碘-131碘化钠用于治疗甲状腺功能亢进症和分化型甲状腺癌。
  • 治疗效应通过发射高能β粒子形式的电离辐射实现。
  • 碘-131碘化钠治疗要求负责患者临床管理的临床医师与实施放射性药物治疗的医师密切合作与沟通。
  • 文件提供关于最佳治疗程序、适当预防措施及特殊情形下治疗的指导。

临床应用与阅片要点

  • 本实践参数供经适当培训和许可的医师在口服碘-131碘化钠治疗良恶性甲状腺疾病时参照,以指导最佳治疗程序、适当预防措施及特殊情形下的处理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This practice parameter was developed collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the Society for Pediatric Radiology (SPR). This practice parameter is intended to guide appropriately trained and licensed physicians in the oral administration of I-131 sodium iodide for the treatment of benign and malignant thyroid diseases.

METHODS: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website ( https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards ) by the Committee on Practice Parameters-Nuclear Medicine and Molecular Imaging of the ACR Commissions on Nuclear Medicine and Molecular Imaging, the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology, the Committee on Practice Parameters-Pediatric Radiology of the ACR Commission on Pediatric Radiology in collaboration with the ACNM, the ARS, the SNMMI, and the SPR.

RESULTS: I-131 sodium iodide is used for the treatment of hyperthyroidism and differentiated thyroid cancer. The therapeutic effect of I-131 sodium iodide is achieved by the emission of ionizing radiation in the form of high-energy beta particles. I-131 sodium iodide therapy requires close cooperation and communication between the clinicians who are responsible for the clinical management of the patient and the physicians who administer radiopharmaceutical therapy. This document provides guidance regarding optimal therapy procedures, appropriate precautions, and therapy in unique situations.

CONCLUSIONS: This practice parameter is designed to assist practitioners in providing appropriate radiologic care for treating benign and malignant thyroid disease with I-131 sodium iodide.

来源:Am J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Trout AT, Boike TP, Avram AM, et al. ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium Iodide. Am J Clin Oncol. 2025. PMID: 40694360. doi:10.1097/COC.0000000000001239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。